Vice President
Regeneron Pharmaceuticals, Inc.
A leading national expert and researcher in personalized medicine, Dr. Shuldiner focuses on the genetics of age-related diseases, including of type 2 diabetes, obesity, osteoporosis, and cardiovascular disease. He is best known for his studies involving Old Order Amish, a homogeneous population ideal for genetic studies. His group reported the first null mutation in the APOC3 gene and its association with low blood triglyceride levels and cardioprotection, which validates treatment for hypertriglyceridemia. His group also identified a common gene variant that reduces the benefit of clopidogrel, which many cardiologists now use to individualize anti-platelet therapy. Dr. Shuldiner is vice president at the Regeneron Genetics Center, a program that focuses on early gene discovery and functional genomics and facilitates drug development. He also serves on the faculty (part-time) at the University of Maryland School of Medicine as the John L. Whitehurst Professor of Medicine and Associate Dean and Director of the Program for Personalized and Genomic Medicine. He has published more than 500 articles and serves on several steering and advisory committees related to his expertise in complex disease genetics and the translation of genetic discoveries to the clinical setting.
Disclosure information not submitted.
Wednesday, March 16, 2022
3:00 PM – 4:00 PM ET
.png)